# A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis

> **NCT02207231** · PHASE3 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 837 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Guselkumab 100 mg
- **DRUG:** Placebo for guselkumab
- **DRUG:** Adalimumab
- **DRUG:** Placebo for adalimumab

## Key facts

- **NCT ID:** NCT02207231
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-26
- **Primary completion:** 2015-09-29
- **Final completion:** 2020-06-17
- **Target enrollment:** 837 (ACTUAL)
- **Last updated:** 2021-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02207231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02207231, "A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02207231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*